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Edited by Ned ManteiAbstract We have reported that histone deacetylase (HDAC)
inhibitors activate a member of the INK4 family, the p19INK4d
gene, causing G1 phase arrest. We report here that HDAC
inhibitor, Trichostatin A, activates another member of the INK4
family, the p18INK4c gene, through its promoter in Jurkat cells.
Interestingly, the activation patterns of the p18INK4c gene were
diﬀerent from those of p19INK4d. Furthermore, mouse embryo
ﬁbroblasts lacking p18Ink4c or p18Ink4c/p19Ink4d were resistant to
the growth inhibitory eﬀects of TSA as compared to their wild-
type counterpart. Our ﬁndings suggest that p18INK4c is involved
in TSA-mediated cell growth inhibition and cooperates with
p19INK4d.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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The histone deacetylase (HDAC) inhibitors are a new class
of cytostatic agents that inhibit the proliferation of tumor cells
in culture and in vivo by inducing cell cycle arrest at G1 or G2/
M phase [1], diﬀerentiation and apoptosis [2,3]. Several com-
pounds are currently in early phase of clinical applications as
one of the most attractive and promising anti-tumor agents for
solid and hematological cancers [4].
Cell-cycle progression is regulated by cyclin-dependent ki-
nases (CDKs) that form complexes with cyclin in a phase-
speciﬁc manner during the cell cycle [5]. Cyclin D-CDK4/6 and
cyclin E-CDK2 play important roles in promoting the transi-
tion from the G1 phase to the S phase of the cell cycle by
phosphorylating the tumor suppressor retinoblastoma protein
(pRB) [5,6]. Activation of cyclin/CDKs is counterbalanced by
CDK inhibitors (CKIs). The ﬁrst family of CKIs, referred to
as the Cip/Kip family, consists of related proteins known as
p21WAF1=Cip1, p27Kip1 and p57Kip2, and each member inhibits a
broader spectrum of cyclin/CDK complexes [7,8]. Previously,
we demonstrated that HDAC inhibitors, such as sodium
butyrate and Trichostatin A (TSA), inhibit cellular prolifera-
tion and induce the expression of the p21WAF1=Cip1 gene in a* Corresponding author. Fax: +81-75-241-0792.
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strongly suggest that HDAC inhibitors induced-growth arrest
can be mediated by a p21WAF1=Cip1-independent molecular
pathway [11,12].
The second family of CDK inhibitors is called the INK4
family (for inhibitors of Cdk4) proteins. The four members of
the INK4 family, designated as p16INK4a, p15INK4b, p18INK4c
and p19INK4d, speciﬁcally and directly bind to CDK4/6 and
inhibit their activities [7,13–15]. Previously, we reported that
HDAC inhibitors activate the p15INK4b gene through its pro-
moter in human immortalized keratinocyte HaCaT [16]. Fur-
thermore, we demonstrated that treatment of Jurkat cells with
TSA signiﬁcantly activated the p19INK4d gene through its
promoter [17]. However, it remains to be elucidated whether
the p18INK4c gene is involved in G1 phase arrest induced by
HDAC inhibitors. Here, we demonstrated that TSA activates
the p18INK4c gene and compared the activation patterns of the
p18INK4c gene by TSA with those of the p19INK4d gene.
Furthermore, to examine the involvement of p18INK4c in TSA-
induced growth arrest, we tested the sensitivity of mouse
embryo ﬁbroblasts lacking p18Ink4c or p18Ink4c/p19Ink4d [18] to
the growth inhibitory eﬀects of TSA.2. Materials and methods
2.1. Cell Culture, cell proliferation studies and treatment with
Trichostatin A
The human T lymphoblastic T cell line, Jurkat (a kind gift from Dr.
J.I. Fujisawa, Kansai Medical University) was maintained in RPMI
1640 medium with 10% fetal bovine serum and incubated at 37 C in a
humidiﬁed atmosphere of 5% CO2. Wild type, p18
Ink4c-null and
p18Ink4c/p19Ink4d double-null mouse embryo ﬁbroblasts (MEFs) (a
kind gift from Dr. M.F. Roussel, St. Jude Children’s Research Hos-
pital) were maintained in DMEM supplemented with 10% fetal bovine
serum as previously described [19]. For the cell proliferation studies,
cells were plated at a density of 5 104 cells in 35 mm-diameter dishes.
Twenty-four hours after cell plating, 5 nM TSA (Wako, Osaka, Japan)
was added to the culture medium. From the ﬁrst day to the ﬁfth day
after plating, the number of viable cells was counted by a Trypan-blue
dye exclusion test. This cell growth study was carried out in triplicate
and repeated at least three times.
2.2. RNA isolation and Northern blot analysis
Jurkat cells were treated with various concentrations of TSA. Total
RNA was isolated from cells grown in a 100-mm diameter dish using a
Sepasol RNA isolation kit (Nacalai Tesque Inc., Kyoto, Japan), and
10 lg of total RNA per lane was used for Northern blot analysis. The
p18INK4c cDNA and p19INK4d cDNA used for the probe were described
previously [17,20]. Northern blot analysis was performed using stan-
dard methods [21]. Expression of mRNA was quantiﬁed by Quantityblished by Elsevier B.V. All rights reserved.
Fig. 1. Northern blot analysis of p18INK4c and p19INK4d mRNA in
Jurkat cells. Jurkat cells were treated, (A) in the presence of various
concentrations of TSA for 18 h, or (B) in the presence of 120 nM TSA
for the indicated times, and the expressions of p18INK4c and p19INK4d
mRNA were examined. Data shown below the blots represent fold
induction in RNA expression normalized by 28S ribosomal RNA as
described in Section 2, and each value was compared with that of the
control without TSA which was estimated as 1.0.
172 T. Yokota et al. / FEBS Letters 574 (2004) 171–175One 4.3.0 Quantitation Software (BIO RAD) and normalized by 28S
ribosomal RNA quantiﬁed by Quantity One 4.3.0 Quantitation Soft-
ware. Each experiment was repeated at least three times.
2.3. Protein isolation and Western blot analysis
The cells were lysed by RIPA buﬀer (50 mM Tris–HCl, pH 7.5, 150
mMNaCl, 1% Triton X-100, 0.1% SDS, and 1% sodium deoxycholate)
for P19INK4d and p18INK4c detection or Lysis buﬀer (50 mM Tris–HCl,
pH 7.5, and 0.1% SDS) for detection of the retinoblastoma (RB) gene
products. The protein extract was boiled for 5 min and loaded onto a
12% (for p18INK4c and p19INK4d detection) or 7% (for pRB detection)
polyacrylamide gel, electrophoresed, and transferred to a nitrocellulose
membrane. A rabbit polyclonal antibody to human p18 (N-20, Santa
Cruz Biotechnology, CA, USA), a mouse monoclonal antibody to
human p19 (DCS-100 from NeoMarkers, Union City, CA, USA) or
pRB (PM-14001A from Pharmingen, Becton-Dickinson Franklin
Lakes, NJ, USA) was used as the primary antibody. The signal was
then developed with the enhanced chemiluminescence system (Amer-
sham Pharmacia Biotech, UK). Expression of the proteins was quan-
tiﬁed by Quantity One 4.3.0 Quantitation Software and normalized by
a-Tubulin. Each experiment was repeated at least three times.
2.4. Plasmid preparation, transient transfection and luciferase assay
As previously reported, an approximately 3.8-kb fragment of 50-
ﬂanking region of human p19INK4d gene was subcloned into the lu-
ciferase reporter plasmid pGVB2 (Nippon Gene), which was termed
p19 ()3814/)2) [22]. Similarly, an approximately 5.2-kb fragment of
50-ﬂanking region of human p18INK4c gene was subcloned into
pGVB2, which was termed p18 ()5786/)514) [20]. Jurkat cells were
transiently transfected with p18INK4c or p19INK4d-luciferase fusion
plasmid, by the DEAE-dextran method as described previously [23].
Twenty-four hours after transfection, various concentrations of TSA
were added, and 48 h after the transfection, the cell lysates were col-
lected for a luciferase assay. Cells were washed twice with PBS and
resuspended in 100 ll of 0.25 M Tris–HCl (pH 7.5). Five cycles of
freeze–thawing were performed in liquid nitrogen/water at 37 C.
Luciferase activities were normalized for the amount of protein in the
cell lysates. Data were analyzed using the Student’s t test. A P value
less than 0.05 was considered signiﬁcant. Each experiment was re-
peated at least three times.3. Results
3.1. TSA increases p18INK4c mRNA levels – diﬀerential
activation pattern of p18INK4c and p19INK4d mRNA by TSA
Among the INK4 family, both p18INK4c and p19INK4d are
normally expressed, whereas p16INK4a and p15INK4b are ho-
mozygously deleted in Jurkat cells [24,25]. We have already
reported that treatment of Jurkat cells with TSA activates
p19INK4d gene, resulting in GI phase arrest [17]. In this study,
we investigated whether TSA activates p18INK4c gene in Jurkat
cells. We found that p18INK4c mRNA was upregulated 18 h
after treatment with TSA (Fig. 1A). These data are consistent
with our previous results showing that TSA inhibits the pro-
liferation of Jurkat cells and that 120–240 nM TSA had cy-
tostatic eﬀects [17].
Interestingly, the activation patterns of the p18INK4c mRNA
were diﬀerent from those of p19INK4d mRNA. The p18INK4c
mRNA was maximally activated by treatment with 120 nM
TSA, whereas p19INK4d mRNA is stimulated in a dose-
dependent manner up to 240 nM TSA (Fig. 1A). Time course
studies showed that p18INK4c mRNA was upregulated 12–18 h
after treatment with 120 nM TSA, whereas p19INK4d mRNA
was upregulated rapidly 3 h after treatment with TSA and was
maximally activated about 6 h after treatment (Fig. 1B). Taken
together, p18INK4c mRNA was upregulated by treatment with
TSA, but maximal activation was seen with a lower dose and a
longer treatment as compared to p19INK4d mRNA.3.2. TSA upregulates the p18INK4c protein – diﬀerential
activation pattern of the p18INK4c and p19INK4d protein by
TSA
Next, Western blot analysis showed that treatment with
diﬀerent concentrations of TSA for 24 h induced the expres-
sion of the p18INK4c protein as well as the p19INK4d protein
(Fig. 2A).
Time course studies indicated that the p18INK4c protein was
signiﬁcantly increased from 12 to 18 h after the treatment with
120 nM TSA, whereas the p19INK4d protein was signiﬁcantly
increased 3 h after the treatment with TSA, and that strong
induction of the p19INK4d protein was observed from 6 to 12 h
after exposure to TSA compared with the treatment with sol-
vent of TSA alone (Fig. 2B). The results of time course study
of the p18INK4c and p19INK4d induction patterns seem to be
well correlated with those of p18INK4c and p19INK4d mRNA
activation pattern.
Because overexpression of p18Ink4c and p19Ink4d induces G1
phase arrest by blocking Cdk4/6 kinase activities and pRB
phosphorylation [13,15], we tested by Western blotting whe-
ther TSA altered the phosphorylation of pRB protein. We
found that about 24 h after treatment, hyperphosphorylated
form of pRB protein began to be converted into a hypo-
phosphorylated form (Fig. 2C).
Collectively, the activation patterns of the p18INK4c gene
were diﬀerent from those of p19INK4d.
3.3. TSA stimulates p18INK4c promoter activity – diﬀerential
activation pattern of the p18INK4c and p19INK4d promoter by
TSA
Because p18INK4c mRNA expression is induced by TSA in
Jurkat cells, we investigated whether TSA could transactivate
the p18INK4c promoter, using a wild-type p18INK4c promoter-
luciferase fusion reporter plasmid, p18 ()5786/)514). Follow-
Fig. 2. Western blot analysis of the p18INK4c, p19INK4d and the pRB
protein. (A) Jurkat cells were treated with various concentrations of
TSA for 24 h and the expressions of the p18INK4c and p19INK4d protein
were examined a-Tubulin (Oncogene Research Product, CA, USA)
was chosen as a loading control in all blots. (B, C) Jurkat cells were
exposed to either DMSO alone ()) or 120 nM TSA (+) for the indi-
cated times. The expressions of the p18INK4c and p19INK4d (B) and the
pRB protein (C) were analyzed. Data shown below the blots represent
fold induction in the protein expression normalized by a-Tubulin as
described in Section 2, and each value was compared with that of the
control without TSA which was estimated as 1.0.
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p18INK4c promoter was maximally activated by treatment with
120 nM TSA (Fig. 3A), while the p19INK4d promoter is stim-
ulated in a dose-dependent manner up to 240 nM TSA
(Fig. 3B).
These results suggest that TSA transactivates the p18INK4c
promoter as well as the p19INK4d promoter, but that their ac-
tivation patterns are remarkably diﬀerent from one another.
Furthermore, the results of the promoter activation of
p18INK4c and p19INK4d seem to be also well correlated with those
of both mRNA activations. Therefore, a possible molecularFig. 3. Activation of p18INK4c and p19INK4d promoter activity in Jurkat ce
p19INK4d-luciferase fusion plasmid, and luciferase activities were measured af
for 24 h. Data are shown as means (bars, SD) ðn ¼ 3Þ, P < 0:05; P < 0:01basis for such diﬀerential activation patterns of both genes may
be explained by diﬀerences in the transcriptional regulation.
3.4. Eﬀect of TSA on the growth of wild type, p18Ink4c-null or
p18Ink4c/p19Ink4d double-null MEFs
We previously demonstrated that MEFs lacking p19Ink4d
were resistant to the growth inhibitory eﬀects of TSA and
concluded that the activation of p19INK4d is involved in growth
inhibition induced by HDAC inhibitors [17]. In this study, to
further analyze the physiological relevance of the induction of
p18INK4c in TSA-induced growth arrest, we examined the
eﬀects of TSA on cell proliferation of wild type and p18Ink4c-
deﬁcient [p18 ()/))] MEFs. p18 ()/)) MEFs grew more rap-
idly than wild-type MEFs in the absence of TSA (Fig. 4A). As
expected, p18Ink4c-null MEFs were more resistant to the
growth inhibitory eﬀects of TSA than were their wild type
counterparts on days 3–5, further supporting a model in which
the endogenous p18Ink4c gene is involved in TSA-mediated cell
growth inhibition (Fig. 4A and B). Moreover, p18Ink4c/p19Ink4d
double-null MEFs were also resistant to the growth inhibitory
eﬀects of TSA on days 3–5 (Fig. 4A and B).
Taken together, these results suggest that the activation of
p18INK4c is involved in growth inhibition induced by TSA.4. Discussion
The results of the present study indicate that the p18INK4c
gene, in addition to the p19INK4d gene, is transcriptionally
activated by TSA in Jurkat cells. Interestingly, the activation
patterns of the p18INK4c gene were diﬀerent from those of
p19INK4d. Our ﬁndings further suggest that p18INK4c is in-
volved in TSA-mediated cell growth inhibition and cooperates
with p19INK4d.
It was reported that treatment of p18Ink4c null and het-
erozygous mice with a chemical carcinogen causes tumor at
an accelerated rate, and that the remaining wild-type allele
of p18Ink4c is normal in tumors derived from heterozygotes
[26]. Recently, we demonstrated that activation of protein
kinase C induces cell growth through suppression of human
p18INK4c expression [20]. Furthermore, leukemogenesis by anlls by TSA. Jurkat cells were transiently transfected with p18INK4c or
ter incubation with medium containing various concentrations of TSA
.
Fig. 4. Eﬀect of TSA on the growth of wild type, p18Ink4c-null or p18Ink4c/p19Ink4d double-null MEFs. (A) One day after inoculation of both MEFs,
TSA at 5 nM ðdÞ was added, and cell growth was compared with control culture ðsÞ. Data represent means of triplicate experiments. Data are
shown as means (bars, SD) ðn ¼ 3Þ, P < 0:05; P < 0:01. (B) Relative cell viability of wild type ðÞ, p18INK4c-null ðQÞ or p18Ink4c/p19Ink4d double-
null ðjÞ MEFs treated with 5 nM TSA versus those that were untreated.
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expression and suppression of ARG kinase activity by
STI571 induces cell cycle arrest through upregulation
of p18INK4c [27]. These reports establish p18Ink4c as a
haploinsuﬃcient tumor suppressor and suggest that its
quantitative decrease may be involved in human tumori-
genesis [26]. On the other hand, so far there was no report
that loss of p19INK4d plays a critical role in tumorigenesis in
humans. Therefore, activation of the p18INK4c gene, which
plays some part in human tumorigenesis, may be of great
signiﬁcance in the therapy or the prevention of malignant
tumors.
Inactivation of p16INK4a has been extensively reported in
most human malignant tumors [15,28], whereas genetic alter-
ations of p18INK4c are rare events [29]. Recently, however, it
was reported that the p18INK4c gene was epigenetically silenced
through its promoter hypermethylation in some tumor types
[30]. These observations suggest that chemotherapy with single
use of HDAC inhibitors may be potentially limited in tumors
with hypermethylation in the p18INK4c promoter; however,
cotreatment with HDAC inhibitors and demethylating agents
could restore p18INK4c expression and be eﬀective in these tu-
mors. In fact, DNA demethylation and HDAC inhibition act
synergistically in re-expression of the hypermethylated genes
such as p16INK4a [31].
Because p18INK4c possesses functional similarity to
p16INK4a as a member of the INK4 family [32], p18INK4c
may be able to compensate for p16INK4a loss commonly
found in human tumors. Therefore, transcriptional activa-
tion of the p18INK4c gene by chemotherapeutic agents may
contribute to a novel approach for chemotherapy or che-
moprevention against cancers that harbor a deletion or
mutations in p16INK4a, which we have termed ‘‘gene-regu-
lating chemotherapy’’ or ‘‘gene-regulating chemoprevention’’
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